Blueprint Medicines Corporation

Good morning. My name is Lydia and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Blueprint Medicine's fourth quarter and full year 2021 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, please press star followed by the number two. Please plan to limit yourself to one question. Thank you. Kristen Hodis, you may begin your conference.

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicine's fourth quarter and full year 2021 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com. Today on our call, Jeff Albers, our Chief Executive Officer, and Kate Haviland, our Chief Operating Officer, will discuss Blueprint Medicine's fourth quarter 2021 business highlights. Christy Rossi, our Chief Commercial Officer, will provide a commercial update. Fuad Naimouni, President, Research and Development, will review our recent clinical progress and highlight upcoming milestones across our growing portfolio. And Mike Lansdell, our Chief Financial Officer, will review our fourth quarter 2021 financial results. Our Chief Medical Officer, Becker Hughes, and our Chief Scientific Officer, Percy Carter, are also joining our call and will be available for Q&A. Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. Now, here's our CEO, Jeff Albers.

Thanks, Kristin, and thank you everyone for joining the call today. In the fourth quarter, we continue to make progress toward expanding the impact of our precision therapies for patients with systemic mastocytosis and lung cancer through our commercial, research, and development efforts. This was particularly notable in four key areas. First, we continue to advance the U.S. launch of Avakit and advance systemic mastocytosis with revenue growth driven by a broadening base of prescribers. Combined with the future planned launch in non-advanced SM, which will be supported by data from our pioneer trial expected mid-year, we continue on the path to realize a potential blockbuster opportunity. Second, all three of our EGFR programs, as well as our CDK2 program, will be in the clinic this quarter, setting up a string of clinical data sets over the next 12 to 18 months. This wave of updates will begin with early clinical data from our Symphony Trial of Blue945 at the AACR meeting in April. Third, we're making progress in bringing our therapies to patients around the world, including in Europe where we recently received a positive CHMP opinion for Avakid in Advanced Systemic Massive Cytosis. Altogether, we now have marketing authorizations or applications under review for Avakid or Gavarito in more than 50 countries supported by our strategic partnerships. And fourth, as we execute on our near-term vision, we're also putting into place drivers of long-term growth, including new research capabilities focused on targeted protein degradation and exciting precision medicine technology that beautifully complements our current kinase platform. All of these activities create opportunities for growth in 2022 and beyond, and we have the right team in place to seize them. And finally, on a personal note, and as we announced last month, I plan to transition my role to executive chairman in April. I came to the decision after thoughtful consideration and succession planning with our board, and I'm excited to make room for Kate Haviland and our exceptional executive team to expand their leadership of the company. I'm tremendously proud of what we've achieved over the last eight years, and I remain deeply committed to driving the success of Blueprint Medicines as executive chairman through the end of this year, and then in a non-executive chairman role thereafter. Now let me turn the call over to Kate to make some brief remarks before we jump into our business updates. Kate?